Abstract
Sibutramine has a dual mode of action. It reduces food intake and attenuates the fall in metabolic rate associated with weight loss. The drug's neurochemical actions can also be distinguished from those of previous centrally acting anti-obesity agents. Clinical trials show that two out of three patients taking sibutramine lose ≥ 5% weight and that the drug can enhance the maintenance of weight loss. Early weight loss predicts long-term success and can be used to guide clinical practice. To maximize the benefits of sibutramine, it is important that patients receive adjunctive diet and lifestyle therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Finer, N. Sibutramine: its mode of action and efficacy. Int J Obes 26 (Suppl 4), S29–S33 (2002). https://doi.org/10.1038/sj.ijo.0802216
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijo.0802216
Keywords
This article is cited by
-
Counterfeit formulations: analytical perspective on anorectics
Forensic Toxicology (2021)
-
Prediction of Weight Loss and Regain Following Dietary, Lifestyle, and Pharmacologic Intervention
Clinical Pharmacology & Therapeutics (2012)
-
Sibutramine promotes amygdala activity under fasting conditions in obese women
Psychopharmacology (2012)
-
5‐HT1A Activation Counteracts Cardiovascular But Not Hypophagic Effects of Sibutramine in Rats
Obesity (2009)
-
Influence of weight reduction by sibutramine on female sexual function
International Journal of Obesity (2006)